Provided by Tiger Fintech (Singapore) Pte. Ltd.

Iovance Biotherapeutics, Inc.

3.62
-0.0150-0.41%
Volume:2.92M
Turnover:10.43M
Market Cap:1.19B
PE:-2.82
High:3.64
Open:3.59
Low:3.51
Close:3.63
Loading ...

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
18 Jan

Wells Fargo Remains a Buy on Iovance Biotherapeutics (IOVA)

TIPRANKS
·
16 Jan

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Vir Biotechnology (VIR)

TIPRANKS
·
12 Jan

Why Iovance Biotherapeutics Inc. (IOVA) Is Skyrocketing

Insider Monkey
·
02 Jan

BRIEF-Iovance Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
21 Dec 2024

Iovance Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
21 Dec 2024

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
21 Dec 2024

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a favorite amongst institutional investors who own 63%

Simply Wall St.
·
03 Dec 2024

Iovance Biotherapeutics promotes Raj Puri to chief regulatory officer

TIPRANKS
·
27 Nov 2024

Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.d., Ph.d. to Chief Regulatory Officer

THOMSON REUTERS
·
27 Nov 2024

Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer

GlobeNewswire
·
27 Nov 2024

Iovance Biotherapeutics, Inc. (IOVA): Among the Most Promising Cancer Stocks According to Hedge Funds

Insider Monkey
·
23 Nov 2024

Iovance Biotherapeutics Inc. (IOVA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts

Insider Monkey
·
22 Nov 2024

Iovance Biotherapeutics call volume above normal and directionally bullish

TIPRANKS
·
16 Nov 2024

TD Cowen Sticks to Its Buy Rating for Iovance Biotherapeutics (IOVA)

TIPRANKS
·
14 Nov 2024

Iovance Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.
·
13 Nov 2024